Press Releases
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
